BACKGROUND: Community pharmacies provide a promising platform for monitoring and improving therapy adherence and providing pharmaceutical care. Structured methods and appropriate software are important tools to increase pharmacist effectiveness and improve health outcomes. In 2006, the Medication Monitoring and Optimization (MeMO) program was introduced in several community pharmacies in the Netherlands. MeMO facilitates targeted and continuous patient-centered pharmaceutical care around chronic medication, such as for osteoporosis, cardiovascular disease, and asthma/chronic obstructive pulmonary disease (COPD).
A dherence to chronic medication has been shown to be suboptimal across many therapeutic areas. Nonadherence has been linked to adverse clinical outcomes, for example, in osteoporosis, asthma/chronic obstructive pulmonary disease (COPD), and cardiovascular diseases. [1] [2] [3] [4] Community pharmacies offer a promising platform for monitoring and improving therapy adherence and for providing medication therapy management. 5, 6 The ability of community pharmacies to monitor long-term dispensing data provides pharmacists with a tool to identify nonadherent patients and approach them for intervention. 7 However, structured methods and appropriate software for such approaches are often lacking, thereby limiting pharmacist effectiveness and reducing the continuity of care and patients' health outcomes. 8 In 2006, the Medication Monitoring and Optimization (MeMO) program was introduced in several community pharmacies in the Netherlands. MeMO facilitates targeted and continuous patient-centered medication therapy management for chronic, preventive medication in the field of cardiovascular diseases, asthma/COPD, and osteoporosis. Since the launch of the program, several studies have assessed clinical and economic outcomes of the MeMO program. [9] [10] [11] [12] [13] In this article, we describe the concept and structure of the MeMO program, its effectiveness, cost-effectiveness, and patient satisfaction with the pharmacies participating in the program.
• Adherence to chronic medication is often suboptimal.
• Pragmatic and structured pharmacist intervention programs can optimize pharmacotherapy and improve therapy adherence.
What is already known about this subject ). In the Netherlands, FDC and SDC are considered usual care by the pharmacy profession guidelines, but they are not routinely performed in all pharmacies. In the MeMO program, FDC and SDC counseling are always performed and documented, using standardized protocols. When patients do not redeem their second prescription, they are contacted to discuss medication problems or administration difficulties. Similarly, patients are contacted when they do not redeem their third prescription on time (in the Netherlands, usually 3 months after the second prescription). After their third prescription, patients enter the continuous phase of MeMO.
Continuous Phase: Detection of Suboptimal Pharmacotherapy
The continuous phase of MeMO has a similar structure for all areas. The purpose of the monitoring phase is to detect suboptimal pharmacotherapy, using monthly searches to identify nonadherent patients in the pharmacists' dispensing database. The different algorithms to detect nonadherence differ between drug classes. For osteoporosis medication and lipid-lowering drugs, nonadherent users are identified as patients who potentially discontinue their medication (nonpersistent users) or patients who continue with low adherence. Nonpersistent users are defined as those patients who did not redeem a new prescription after the theoretical end date of their previous prescription, using a margin of 30 days. Low adherence was defined as having medication coverage for less than 80% of the days from initiation of therapy to the end date of their last prescription. In the asthma/COPD program, patients also need to have an additional risk factor as specified in the section below.
Osteoporosis Medication. For patients identified as potentially nonadherent, medication profiles are inspected manually to determine possible reasons for discontinuations. Valid
■■ Methods Overview and Structure of the MeMO Program
Pharmacies participating in the MeMO program use a pharmacist information system that stores the medication history of enlisted patients. These databases can be queried using search algorithms, for example, to select nonadherent patients or patients receiving specific medications. In the Netherlands, patients show a high commitment to a single ("their") pharmacy.
14 Therefore, these searches can detect nonadherence. Several studies have used prescription data to study therapy adherence. 15, 16 Pharmacists new to the MeMO program are supervised in implementation of the program and follow courses to perform standardized database queries and to conduct patient interventions (www.pharmapartners.nl [in Dutch]). 17 A schematic overview of the MeMO program is shown in Figure 1 . Each part is more thoroughly explained in this section.
Initiation Phase: Structured Counseling and Active Monitoring
When patients redeem their first prescription of a newly initiated chronic medication, the pharmacy team provides verbal and written information about the medication's clinical effectiveness and mechanism of action, the time that it will usually take to notice the drug's effects, the dosing regimen, potential side effects, and instructions on proper administration of the medication (First Dispense Counseling [FDC] ). In The Netherlands, a follow-up assessment after 2 weeks is common practice by physicians, in order to monitor effects of treatment on disease symptoms. After this follow-up assessment, a second prescription (for 3 months) is prescribed. When patients redeem their second prescription in the pharmacy (usually also after 2 weeks), drug use, in particular, is evaluated. This practice contributes to safe and responsible drug use and prevents wasting of medication. The second counseling session focuses on side effects, beliefs and expectations, and discom- Asthma/COPD Medication. For asthma/COPD medication, only "high risk" nonadherent patients are identified for intervention. These are defined as patients having received at least 2 short courses of oral corticosteroids and having discontinued respiratory maintenance medication or showing low adherence (< 80%). To increase the likelihood of identifying COPD patients (instead of older asthma patients), an age threshold of ≥ 50 years is used, preferably in combination with a recorded comorbidity of COPD (if available). Asthma patients are identified based on an age threshold of ≤ 50 years. 18, 19 The suspected diagnosis is confirmed with the prescribing physician before the intervention.
Continuous Phase: Structured Interventions
Patients with suspected suboptimal pharmacotherapy are selected for structured interventions in the MeMO program. For patients using osteoporosis and lipid-lowering drugs, those selected are mainly (intentionally or unintentionally) nonadherent patients. In the asthma/COPD program, these may also include patients with drug therapy problems (such as inhalation technique errors). The interventions are tailored to patients' needs and can be divided into medication-related interventions and lifestyle interventions.
Medication-Related Interventions. Elements in the counseling include side effects of medication, information on the benefits and long-term effects of adherence, advice for integrating chronic drug therapy in daily routine, and motivational interviewing to improve medication adherence. In some cases, the pharmacy team also supported daily drug use with practical advice or unit-dose drug dispensing systems, especially when cognitive problems (e.g., forgetfulness) were the cause of nonadherence. For some interventions, the prescriber is involved, for example, when dose or drug changes are recommended. Note that the way these recommendations are communicated could differ per individual patient and/or pharmacy (setting) and that recommendations are not always followed. In the MeMO asthma/COPD program, additional disease-specific interventions include repeating inhalation device instructions. Disease-monitoring questionnaires are also used in this program, namely the Asthma Control Questionnaire (ACQ) 20 and the Clinical COPD Questionnaire (CCQ) 21 for asthma and COPD patients, respectively. Lifestyle Interventions. In addition to interventions focusing on optimal use of medication, lifestyle recommendations are often provided. Lifestyle interventions include smoking cessation, exercise advice, or dietary recommendations. If needed, the pharmacist suggests that patients schedule an appointment with a physiotherapist or dietician. In general, when lifestyle interventions are deemed necessary, patients are also recommended to contact their prescribing physicians to maintain continuity of care.
Continuous Phase: Evaluation
After intervention, medication use is extensively monitored and evaluated. Depending on the intervention, extra telephone calls can be made with the patient or prescriber, or reminders can be sent to the patient. In the MeMO asthma/COPD program, patients are scheduled for in-person follow-up visits (generally after 3 months) to reevaluate disease status using the ACQ or CCQ questionnaires.
■■ Results
The following section provides an overview of published data on the effectiveness, cost-effectiveness, and patient satisfaction of the MeMO program. For detailed descriptions of the methods and results of the studies we refer to the literature.
9-13
Impact on Medication Adherence and Effectiveness Osteoporosis. A total of 227 patients, in 13 pharmacies, who initiated osteoporotic therapy, received structured FDC and SDC counseling, and their medication use was monitored in the MeMO program. The effectiveness of the program on therapy adherence was assessed and compared with a historical cohort of 408 patients from the same pharmacies who initiated osteoporotic therapy before the MeMO program was implemented, receiving usual care. Usual care included FDC and SDC but no continuous monitoring. 9 Therapy discontinuation after 1 year was 16.1% in the MeMO patients, compared with 31.7% in the control patients (P < 0.001; Figure 2 ). In a recently completed follow-up study (495 patients in the MeMO program and 442 control patients), similar results were observed, with 32.8% discontinuing in the control group and 19.0% in the MeMO group (P < 0.001). 22 In addition, data from follow-up studies showed that the patients in the MeMO program maintained high levels of adherence in the second year of follow-up.
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Lipid-Lowering Drugs. The impact of the MeMO lipid-lowering drugs program on adherence was assessed using a similar study design as that used in the osteoporosis program. 12 A total of 500 patients received MeMO care; these were compared with 502 historical controls. After 1 year, the therapy discontinuation rate was 13.6% in the MeMO cohort and 25.9% in the control group (P < 0.001; Figure 3 ). During a 1-year followup study, the discontinuation rate in the MeMO group was reduced even further to less than 5% (unpublished data).
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Asthma/COPD. A pilot study with 31 participants has explored the effectiveness of the asthma/COPD program. 23 In the pilot study, ACQ and CCQ questionnaires were given to patients at the start of the MeMO program and after 3 months. 20, 21 Despite the low number of participants, the results showed marked improvements in ACQ and CCQ questionnaire scores. The ACQ scores 3 months after the intervention had improved from 1.65 to 1.12 (P < 0.05). CCQ scores had improved nonsignificantly from 1.99 to 1.51 (P = 0.06), implicating a clinically relevant improvement in 44% of the asthma patients and 46% of the COPD patients. Effects of the program on adherence in the pilot program were inconclusive, likely due to the low patient numbers.
Patient Satisfaction
Osteoporosis. A satisfaction questionnaire was sent out to patients after their third prescription. 24 The response rate was 63%. Almost all respondents (93%) were satisfied with the information provided by their community pharmacy. The majority (69%) indicated that they had gained knowledge of the effectiveness and administration of their medication. Onethird of participants had received this information only from their pharmacy, while half had also received information from their physician or nurse. Only a few participants (8%) had privacy concerns regarding counseling by the pharmacy team.
Lipid-Lowering Drugs.
A patient satisfaction survey was sent to participating patients, with a response rate of 54%. 12 Almost all participants (92%) in the MeMO program were satisfied with expertise and the information provided by the pharmacy; half of the patients (52%) were more satisfied with their pharmacy after the MeMO program than before the counseling sessions. The majority of patients (74%) mentioned that their knowledge had increased on the medication effectiveness and administration and on the importance of therapy adherence. One-quarter of patients said that the pharmacy was their only source of information regarding the effectiveness and administration of their drugs.
Asthma/COPD. This study is still ongoing, so no results on patient satisfaction have yet been obtained.
Cost-Effectiveness
Osteoporosis. The cost-effectiveness of the MeMO bisphosphonates program was assessed using a modeling study. 10, 11 The model included intervention costs for the additional time spent on patient care by the pharmacy team. Because clinical parameters such as bone density could not be accessed in the pharmacies, drug adherence levels were linked to clinical outcomes using data from an observational study. 25 The consequences of nonadherence assessed were fractures (such as hip, wrist, and vertebral fractures), costs of these fractures, and quality of life measured in quality-adjusted life-years (QALYs). Over a modeled time-window of 3 years, MeMO osteoporosis was found to be cost-effective in 52,000 patients yearly, initiating osteoporotic therapy with an incremental cost-effectiveness ratio of €16,000 per QALY gained. Costs in the MeMO program included the additional medication costs from improved 
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adherence and a fee for the time investment of the pharmacy. However, these costs were partly offset by the prevention of 337 osteoporotic fractures, compared with the usual-care group. These fractures accounted for a total loss of 46.5 QALYs. When lower drug costs were assumed in the model (likely in situations of generic prescribing or therapeutic substitution), the model indicated that MeMO could be a dominating strategy (i.e., resulting in clinical benefits as well as cost savings). The main drivers of cost-effectiveness were a marked reduction in osteoporotic fractures, in associated health care costs, and in increased medication costs from higher adherence (Figure 4 ).
Lipid-Lowering Drugs.
Since lipid-lowering drugs are often prescribed to be used life-long, a pharmacoeconomic model was used to estimate the life-long costs and clinical effects of increasing statin therapy adherence. 13 This model included intervention costs for the additional time spent on patient care by the pharmacy team. Large clinical trials on the effectiveness of statins on cardiovascular events-namely, myocardial infarction (MI), stroke, and revascularization-were used, both from primary and secondary prevention populations. [26] [27] [28] Efficacy data were adjusted for therapy adherence, by assuming that patients who had discontinued were "treated" with placebo. Data from Dutch observational studies were used to calibrate the model. 13 So modeled, the MeMO program resulted in considerable clinical benefits. According to a model using 1,000 primary (40%) and secondary (60%) prevention patients, the MeMO program resulted in a reduction of 7 nonfatal strokes, 2 fatal strokes, 16 nonfatal MIs, 7 fatal MIs, and 16 revascularizations over patients' lifetimes ( Figure 5 ). Importantly, drug costs for statins are relatively low in the Netherlands because of generic substitution policies. 29 This low cost limited the influence of improved adherence on drug costs in the model. The cost-effective aspect was favorable for the primary prevention population (around €5,000 per QALY gained) and dominating for the secondary prevention population (lower costs and more health gains).
Asthma/COPD.
A larger follow-up of the program is currently ongoing, targeted specifically toward COPD patients. Economic consequences, for example, from exacerbations, will be measured in order to perform a pharmacoeconomic evaluation. 3 Quality of life will be included by mapping the CCQ to EQ-5D utilities (EuroQol Group, Rotterdam, The Netherlands) suitable for economic analyses. A mapping study set up for this purpose is currently ongoing, with preliminary results presented. 30 
■■ Discussion
The MeMO program facilitates structured and continuous medication therapy management across different chronic therapy areas. The effectiveness, patient satisfaction, and cost-effectiveness of MeMO have been studied extensively. The intensive counseling at the initiation of chronic therapies plays an integral role in the patients' adherence levels. Using periodic monitoring of drug use, interventions can be targeted at patients actually requiring counseling. Targeted pharmacy interventions are time-efficient and therefore are likely to improve the cost-effectiveness of the program. 31 Pharmacists In the Netherlands, the pharmacist's role has shifted from a compounder, dispenser, and specialist of medication toward a patient-oriented health care professional. Together with this role change, a shift in reimbursement systems is inevitable. In the future, the primary source of income of pharmacists may be earned by providing continuous medication therapy management. Recently, the Dutch health care authorities have defined several pharmacy services for which the pharmacist can be reimbursed separately from the dispense fees. Currently, the Dutch pharmacists association and health insurance companies are discussing appropriate structures and prices. However, because of the large diversity in types of services offered, more research is warranted, including cost-effectiveness and the role of the pharmacist in multidisciplinary patient-centered care. The MeMO program shows that such roles are possible and may lead to more effective and cost-effective health care. New MeMO programs, including diabetes mellitus care and antithrombotic drugs, are planned for future research. Implementation of community pharmacy-led medication therapy management programs targeting other chronic medications, such as those for human immunodeficiency virus or Crohn's disease, are also likely to contribute to increased therapy adherence. 32 
■■ Conclusion
The MeMO program is an effective method of improving patients' adherence to chronic medication in the areas of osteoporosis, lipid-lowering drugs, and asthma/COPD. By specific targeting of patients demonstrating nonadherence, the program showed favorable cost-effectiveness. Because of their potential to improve therapy adherence, pharmacists can play a valuable role in chronic patient-centered care. using the MeMO program were able to improve medication adherence in patient populations with different types of chronic medications. Internal personal communications indicated that the participating pharmacists were enthusiastic about the program, the patient involvement, the multidisciplinary approach, and the results of the program.
An advantage of the Dutch health care system to pharmaceutical projects such as MeMO is that patients' loyalty to a single pharmacy is high.
14 Moreover, many pharmacies exchange medication histories and even clinical parameters between hospitals, general practitioners, and other pharmacies, using local networks. This exchange ensures complete medication histories to assess therapy use, such as adherence.
Limitations
Intensive collaborations are not always in place and exist only on regional levels. Although a national electronic health record system has been a discussion point for the last few years, it has not been implemented in the Netherlands, mainly because of ongoing privacy and security issues. In countries without a national electronic health records system, such as the United States, the MeMO program can be valuable, but a couple of preconditions need to be met. While structured first-and seconddispense counseling could be relatively easily implemented, for the continuous phase of MeMO, access to a complete overview of patients' medication records is essential. Encouraging patients to sign up for and obtain their medications from only a single pharmacy (or pharmacy chain) could enable this access. Alternatively, collaborations and data exchange on regional levels could be established in order to obtain patients' complete medication records. In addition, the correct use of medication therapy management programs such as MeMO depends on appropriate pharmacist software systems. 17 With adequate software systems and standardized search algorithms, the pharmacist can automatically and efficiently identify patients with suboptimal drug use. Besides these regulatory issues, personal assessment by the pharmacy team remains necessary to optimize patients' medication use, as well as to exclude factors that could justify discontinuation of therapy, such as relocation of patients, holidays, clinical reasons, or death. Signing up for a single pharmacy establishes a better relationship between pharmacist and patient and improves mutual acceptance, which forms the basis for providing optimal pharmaceutical care and medication therapy management.
Lastly, community pharmacists are often limited in their ability to evaluate the medication use of patients because they do not always possess information about the physicians' diagnoses. Instead, they often have to derive a "suspected" diagnosis based on current prescriptions and prescription history. Having access to the actual diagnosis would greatly increase the ability of pharmacists to optimize tailored patient-centered interventions.
